Interferon and Interferon-stimulated Genes in HBV Treatment

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Dec 19

PMID 36531993

Authors

Qirong Li

Baozhen Sun

Yue Zhuo

Ziping Jiang

Rong Li

Chao Lin

Ye Jin

Yongjian Gao

Dongxu Wang

Affiliations

Soon will be listed here.

Abstract

Human hepatitis B virus (HBV) is a small enveloped DNA virus with a complex life cycle. It is the causative agent of acute and chronic hepatitis. HBV can resist immune system responses and often causes persistent chronic infections. HBV is the leading cause of liver cancer and cirrhosis. Interferons (IFNs) are cytokines with antiviral, immunomodulatory, and antitumor properties. IFNs are glycoproteins with a strong antiviral activity that plays an important role in adaptive and innate immune responses. They are classified into three categories (type I, II, and III) based on the structure of their cell-surface receptors. As an effective drug for controlling chronic viral infections, Type I IFNs are approved to be clinically used for the treatment of HBV infection. The therapeutic effect of interferon will be enhanced when combined with other drugs. IFNs play a biological function by inducing the expression of hundreds of IFN-stimulated genes (ISGs) in the host cells, which are responsible for the inhibiting of HBV replication, transcription, and other important processes. Animal models of HBV, such as chimpanzees, are also important tools for studying IFN treatment and ISG regulation. In the present review, we summarized the recent progress in IFN-HBV treatment and focused on its mechanism through the interaction between HBV and ISGs.

Citing Articles

Ethanol Disrupts the Protective Crosstalk Between Macrophages and HBV-Infected Hepatocytes.

Ganesan M, Pathania A, Bybee G, Kharbanda K, Poluektova L, Osna N Biomolecules. 2025; 15(1.

PMID: 39858451 PMC: 11761873. DOI: 10.3390/biom15010057.

Chronic Hepatitis B Genotype C Mouse Model with Persistent Covalently Closed Circular DNA.

Seo D, Hur W, Won J, Han J, Yoon S, Bae S Viruses. 2025; 16(12.

PMID: 39772197 PMC: 11680097. DOI: 10.3390/v16121890.

Hepatitis B virus-induced cirrhosis: Mechanisms, global variations, and treatment advances.

Cheng J, Shan G, Wan H, Liu Y, Zhang Y, Shi W World J Hepatol. 2025; 16(12):1515-1523.

PMID: 39744198 PMC: 11686541. DOI: 10.4254/wjh.v16.i12.1515.

Unraveling 's biofunction in human disease.

Du J, Luo H, Ye S, Zhang H, Zheng Z, Liu K Front Oncol. 2024; 14:1436576.

PMID: 39737399 PMC: 11682996. DOI: 10.3389/fonc.2024.1436576.

Chinese medicine in the treatment of chronic hepatitis B: The mechanisms of signal pathway regulation.

Zheng S, Qi W, Xue T, Zao X, Xie J, Zhang P Heliyon. 2024; 10(20):e39176.

PMID: 39640799 PMC: 11620126. DOI: 10.1016/j.heliyon.2024.e39176.

References

Li Y, Liu Z, Hui L, Liu X, Feng A, Wang W . Transbody against virus core protein potently inhibits hepadnavirus replication in vivo: evidence from a duck model of hepatitis B virus. Br J Pharmacol. 2017; 174(14):2261-2272. PMC: 5481659. DOI: 10.1111/bph.13811. View

Sunbul M . Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014; 20(18):5427-34. PMC: 4017058. DOI: 10.3748/wjg.v20.i18.5427. View

Lanford R, Chavez D, Brasky K, Burns 3rd R, Rico-Hesse R . Isolation of a hepadnavirus from the woolly monkey, a New World primate. Proc Natl Acad Sci U S A. 1998; 95(10):5757-61. PMC: 20452. DOI: 10.1073/pnas.95.10.5757. View

Menne S, Cote P . The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol. 2007; 13(1):104-24. PMC: 4065868. DOI: 10.3748/wjg.v13.i1.104. View

Namineni S, OConnor T, Faure-Dupuy S, Johansen P, Riedl T, Liu K . A dual role for hepatocyte-intrinsic canonical NF-κB signaling in virus control. J Hepatol. 2020; 72(5):960-975. DOI: 10.1016/j.jhep.2019.12.019. View

Xia Y, Guo H . Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral Res. 2020; 180:104824. PMC: 7387223. DOI: 10.1016/j.antiviral.2020.104824. View

Liu J, McIntosh H, Lin H . Chinese medicinal herbs for chronic hepatitis B. Cochrane Database Syst Rev. 2001; (1):CD001940. PMC: 7017971. DOI: 10.1002/14651858.CD001940. View

Imam H, Kim G, Mir S, Khan M, Siddiqui A . Interferon-stimulated gene 20 (ISG20) selectively degrades N6-methyladenosine modified Hepatitis B Virus transcripts. PLoS Pathog. 2020; 16(2):e1008338. PMC: 7046284. DOI: 10.1371/journal.ppat.1008338. View

Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N . Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology. 2001; 34(3):573-7. DOI: 10.1053/jhep.2001.26819. View

10.

Wong D, Cheung A, ORourke K, Naylor C, Detsky A, Heathcote J . Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119(4):312-23. DOI: 10.7326/0003-4819-119-4-199308150-00011. View

11.

Wang T, Wang X, Zhuo Y, Si C, Yang L, Meng L . Antiviral activity of a polysaccharide from Radix Isatidis (Isatis indigotica Fortune) against hepatitis B virus (HBV) in vitro via activation of JAK/STAT signal pathway. J Ethnopharmacol. 2020; 257:112782. DOI: 10.1016/j.jep.2020.112782. View

12.

Liu G, Lee J, Parker Z, Acharya D, Chiang J, van Gent M . ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity. Nat Microbiol. 2021; 6(4):467-478. PMC: 8103894. DOI: 10.1038/s41564-021-00884-1. View

13.

Sajid M, Ullah H, Yan K, He M, Feng J, Shereen M . The Functional and Antiviral Activity of Interferon Alpha-Inducible IFI6 Against Hepatitis B Virus Replication and Gene Expression. Front Immunol. 2021; 12:634937. PMC: 8047077. DOI: 10.3389/fimmu.2021.634937. View

14.

Ito H, Kanbe A, Hara A, Ishikawa T . Induction of humoral and cellular immune response to HBV vaccine can be up-regulated by STING ligand. Virology. 2019; 531:233-239. DOI: 10.1016/j.virol.2019.03.013. View

15.

Zhang L, Wang G, Hou W, Li P, Dulin A, Bonkovsky H . Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology. 2010; 51(2):690-8. PMC: 2930399. DOI: 10.1002/hep.23384. View

16.

Pindel A, Sadler A . The role of protein kinase R in the interferon response. J Interferon Cytokine Res. 2010; 31(1):59-70. DOI: 10.1089/jir.2010.0099. View

17.

Terrault N, Bzowej N, Chang K, Hwang J, Jonas M, Murad M . AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2015; 63(1):261-83. PMC: 5987259. DOI: 10.1002/hep.28156. View

18.

Bawono R, Abe T, Qu M, Kuroki D, Deng L, Matsui C . HERC5 E3 ligase mediates ISGylation of hepatitis B virus X protein to promote viral replication. J Gen Virol. 2021; 102(10). DOI: 10.1099/jgv.0.001668. View

19.

Chen K, Liu J, Liu S, Xia M, Zhang X, Han D . Methyltransferase SETD2-Mediated Methylation of STAT1 Is Critical for Interferon Antiviral Activity. Cell. 2017; 170(3):492-506.e14. DOI: 10.1016/j.cell.2017.06.042. View

20.

Wang Y, Fan X, Song Y, Liu Y, Liu R, Wu J . SAMD4 family members suppress human hepatitis B virus by directly binding to the Smaug recognition region of viral RNA. Cell Mol Immunol. 2020; 18(4):1032-1044. PMC: 7223975. DOI: 10.1038/s41423-020-0431-x. View